Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Kidney cancer

CXCR4—a prognostic factor for renal cell carcinoma?

Nature Reviews Urology volume 11, page 247 (2014)Cite this article

Subjects

CXC chemokine receptor 4 (CXCR4) expression has been found to correlate with prognosis in a training set of 125 patients and a validation set of 100 patients with clear cell renal cell carcinoma (ccRCC). Immunohistochemical staining intensity increased in association with TNM stage, and high levels were predictive of overall survival, especially for patients with early-stage ccRCC. Combining CXCR4 expression with TNM stage improved prediction of overall survival compared with either measure alone.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. An, H. et al. High CXC chemokine receptor 4 expression is an adverse prognostic factor in patients with clear-cell renal cell carcinoma. Br. J. Cancer 10.1038/bjc.2014.179

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

CXCR4—a prognostic factor for renal cell carcinoma?. Nat Rev Urol 11, 247 (2014). https://doi.org/10.1038/nrurol.2014.93

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrurol.2014.93

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing